ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

被引：62

作者：

Ledermann, J. A. ^{[1
]}

Matias-Guiu, X. ^{[2
,3
,4
]}

Amant, F. ^{[5
,6
]}

Concin, N. ^{[7
,8
]}

Davidson, B. ^{[9
,10
]}

Fotopoulou, C. ^{[11
]}

Gonzalez-Martin, A. ^{[12
,13
]}

Gourley, C. ^{[14
]}

Leary, A. ^{[15
]}

Lorusso, D. ^{[16
,17
]}

Banerjee, S. ^{[18
,19
]}

Chiva, L. ^{[20
]}

Cibula, D. ^{[21
,22
]}

Colombo, N. ^{[23
,24
]}

Croce, S. ^{[25
]}

Eriksson, A. G. ^{[10
,26
]}

Falandry, C. ^{[27
,28
]}

Fischerova, D. ^{[21
,22
]}

Harter, P. ^{[8
,29
]}

Joly, F. ^{[30
]}

Lazaro, C. ^{[31
]}

Lok, C. ^{[6
]}

Mahner, S. ^{[29
,32
]}

Marme, F. ^{[29
,33
,34
]}

Marth, C. ^{[7
]}

McCluggage, W. G. ^{[35
]}

Mcneish, I. A. ^{[11
]}

Morice, P. ^{[36
]}

Nicum, S. ^{[1
]}

Oaknin, A. ^{[37
]}

Perez-Fidalgo, J. A. ^{[38
]}

Pignata, S. ^{[39
]}

Ramirez, P. T. ^{[40
]}

Ray-Coquard, I. ^{[41
]}

Romero, I. ^{[42
]}

Scambia, G. ^{[16
,17
]}

Sehouli, J. ^{[43
,44
]}

Shapira-Frommer, R. ^{[45
]}

Sundar, S. ^{[46
,47
]}

Tan, D. S. P. ^{[48
,49
,50
,51
]}

Taskiran, C. ^{[38
]}

van Driel, W. J. ^{[40
]}

Vergote, I. ^{[52
]}

Planchamp, F. ^{[37
]}

Sessa, C. ^{[48
,49
,50
,51
]}

Fagotti, A. ^{[6
]}

机构：

[1] UCL, UCL Canc Inst, Dept Oncol, London, England

[2] CIBERONC, Madrid, Spain

[3] Univ Lleida, Hosp Univ Arnau Vilanova, Dept Pathol, IRBLLEIDA, Lleida, Spain

[4] Univ Barcelona, Hosp Univ Bellvitge, Dept Pathol, IDIBELL, Barcelona, Spain

[5] Univ Hosp Leuven, Leuven Canc Inst, Dept Gynaecol Oncol, Leuven, Belgium

[6] Netherlands Canc Inst, Ctr Gynecol Oncol Amsterdam, Dept Gynecol, Amsterdam, Netherlands

[7] Med Univ Innsbruck, Dept Obstet & Gynaecol, Innsbruck, Austria

[8] Evang Kliniken Essen Mitte, Dept Gynaecol & Gynaecol Oncol, Essen, Germany

[9] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, Oslo, Norway

[10] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway

[11] Imperial Coll London, Fac Med, Dept Surg & Canc, London, England

[12] Clin Univ Navarra, Canc Ctr, Dept Med Oncol, Madrid, Spain

[13] Clin Univ Navarra, Canc Ctr, Program Solid Tumours Cima, Madrid, Spain

[14] Univ Edinburgh, Inst Genet & Canc, Canc Res UK Scotland Ctr, Edinburgh, Midlothian, Scotland

[15] Inst Gustave Roussy, Dept Med, Villejuif, France

[16] Fdn Policlin Univ A Gemelli IRCCS, Div Gynecol Oncol, Rome, Italy

[17] Univ Cattolica Sacro Cuore, Dept Woman Child & Publ Hlth, Rome, Italy

[18] Royal Marsden NHS Fdn Trust, London, England

[19] Inst Canc Res, London, England

[20] Clin Univ Navarra, Dept Gynaecol & Obstet, Canc Ctr, Navarra, Spain

[21] Charles Univ Prague, Fac Med 1, Dept Gynecol Obstet & Neonatol, Prague, Czech Republic

[22] Gen Univ Hosp Prague, Prague, Czech Republic

[23] Ist Europeo Oncol IRCCS, Dept Gynecol Oncol, Milan, Italy

[24] Univ Milano Bicocca, Dept Med & Surg, Milan, Italy

[25] Bergonie Inst, Dept Biopathol, Bordeaux, France

[26] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Gynecol Oncol, Div Canc Med, Oslo, Norway

[27] Hosp Civils Lyon, Inst Aging, Lyon, France

[28] Univ Lyon 1, CarMeN Lab, INSERM,U1060, INRAE,U1397,Hosp Civils Lyon, Pierre Benite, France

[29] Arbeitsgemeinschaft Gynakol Onkol AGO Study Grp, Ravensburg, Germany

[30] Univ Caen Normandy, Ctr Francois Baclesse, Dept Med Oncol, GINECO Grp, Caen, France

[31] CIBERONC, Hereditary Canc Program, Catalan Inst Oncol, ICO,IDIBELL, Barcelona, Spain

[32] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Obstet & Gynecol, Munich, Germany

[33] Univ Hosp Mannheim, Dept Obstet & Gynecol, Mannheim, Germany

[34] Heidelberg Univ, Med Fac Mannheim, Mannheim, Germany

[35] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland

[36] Gustave Roussy Canc Campus, Dept Gynecol Surg, Villejuif, France

[37] Hosp Univ Vall Hebron, Gynaecol Canc Programme, Vall Hebron Inst Oncol VHIO, Vall Hebron Barcelona Hosp Campus, Barcelona, Spain

[38] Hosp Clin Univ, Dept Med Oncol, INCLIVA, CIBERONC, Valencia, Spain

[39] IRCCS Fdn Pascale, Ist Nazl Tumori Napoli, Dept Urol & Gynecol, Naples, Italy

[40] Houston Methodist Hosp, Dept Obstet & Gynecol, Houston, TX USA

[41] Univ Claude Bernard, Ctr Leon Berard, Dept Med Oncol, Lyon, France

[42] Inst Valenciano Oncol, Dept Med Oncol, Valencia, Spain

[43] North Eastern German Soc Gynecol Oncol NOGGO, Berlin, Germany

[44] Charite Berlin Univ Med, Ctr Oncol Surg, Dept Gynecol, Berlin, Germany

[45] Sheba Med Ctr, Ramat Gan, Israel

[46] Univ Birmingham, Inst Canc & Genom Sci, Birmingham, W Midlands, England

[47] City Hosp, Pan Birmingham Gynaecol Canc Ctr, Birmingham, W Midlands, England

[48] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore

[49] Natl Univ Singapore, Natl Univ Singapore NUS Ctr Canc Res, Yong Loo Lin Sch Med, Singapore, Singapore

[50] Natl Univ Singapore, Canc Sci Inst, Singapore, Singapore

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷 / 03期

关键词：

chemotherapy; maintenance treatment; molecular biology; ovarian cancer; pathology; surgery; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; TUBAL INTRAEPITHELIAL CARCINOMA; SEROUS BORDERLINE TUMORS; NEOADJUVANT CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; ADJUVANT CHEMOTHERAPY; MAINTENANCE THERAPY; FALLOPIAN-TUBE; OPEN-LABEL; QUALITY INDICATORS;

D O I：

10.1016/j.annonc.2023.11.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early -stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.

引用

页码：248 / 266

页数：19

共 10 条

[1] ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Colombo, N.
Sessa, C.
du Bois, A.
Ledermann, J.
McCluggage, W. G.
McNeish, I.
Morice, P.
Pignata, S.
Ray-Coquard, I.
Vergote, I.
Baert, T.
Belaroussi, I.
Dashora, A.
Olbrecht, S.
Planchamp, F.
Querleu, D.
Banerjee, S.
Blecharz, P.
Bruchim, I.
Cibula, D.
Concin, N.
Davidson, B.
Devouassoux-Shisheboran, M.
Ferrero, A.
Glasspool, R.
Gonzalez-Martin, A.
Heinzelmann-Schwarz, V.
Joly, F.
Kim, J. W.
Kridelka, F.
Lorusso, D.
Mahner, S.
Mikami, M.
Mirza, M. R.
Nicum, S.
O'Donnell, D. M.
Pautier, P.
Rodolakis, A.
Sehouli, J.
Selcukbiricik, F.
Singh, N.
Tan, D. S. P.
Timmerman, D.
Tognon, G.
van der Velden, J.
Witteveen, P. O.
Zeimet, A. G.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (04) : 728 - 760
[2] ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Colombo, N.
Sessa, C.
du Bois, A.
Ledermann, J.
McCluggage, W. G.
McNeish, I.
Morice, P.
Pignata, S.
Ray-Coquard, I.
Vergote, I.
Baert, T.
Belaroussi, I.
Dashora, A.
Olbrecht, S.
Planchamp, F.
Querleu, D.
Baert, T.
Banerjee, S.
Belaroussi, I.
Blecharz, P.
Bruchim, I.
Cibula, D.
Colombo, N.
Concin, N.
Davidson, B.
Dashora, A.
Devouassoux-Shisheboran, M.
du Bois, A.
Ferrero, A.
Glasspool, R.
Gonzalez-Martin, A.
Heinzelmann-Schwarz, V.
Joly, F.
Kim, J. W.
Kridelka, F.
Ledermann, J.
Lorusso, D.
Mahner, S.
McCluggage, W. G.
McNeish, I.
Mikami, M.
Mirza, M. R.
Morice, P.
Nicum, S.
Olbrecht, S.
O'Donnell, D. M.
Pautier, P.
Planchamp, F.
Pignata, S.
Querleu, D.
ANNALS OF ONCOLOGY, 2019, 30 (05) : 672 - 705
[3] Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
Wilson, M. K.
Pujade-Lauraine, E.
Aoki, D.
Mirza, M. R.
Lorusso, D.
Oza, A. M.
du Bois, A.
Vergote, I.
Reuss, A.
Bacon, M.
Friedlander, M.
Gallardo-Rincon, D.
Joly, F.
Chang, S. -J.
Ferrero, A. M.
Edmondson, R. J.
Wimberger, P.
Maenpaa, J.
Gaffney, D.
Zang, R.
Okamoto, A.
Stuart, G.
Ochiai, K.
ANNALS OF ONCOLOGY, 2017, 28 (04) : 727 - 732
[4] Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
Kerr, K. M.
Bubendorf, L.
Edelman, M. J.
Marchetti, A.
Mok, T.
Novello, S.
O'Byrne, K.
Stahel, R.
Peters, S.
Felip, E.
ANNALS OF ONCOLOGY, 2014, 25 (09) : 1681 - 1690
[5] Limited implementation of the ESMO-ESGO (European Society of Gynaecological Oncology)-ESTRO (European Society for Radiotherapy and Oncology) consensus conference recommendations (CCR) on endometrial cancer (EC)
Sessa, C.
Colombo, N.
Creutzberg, C. L.
Concin, N.
Wimberger, P.
Marinoni, K. A.
Douillard, J-Y.
Torri, V.
Rauh, S.
ANNALS OF ONCOLOGY, 2020, 31 : S638 - S638
[6] Terminology for cone dimensions after local conservative treatment for cervical intraepithelial neoplasia and early invasive cervical cancer: 2022 consensus recommendations from ESGO, EFC, IFCPC, and ESP
Kyrgiou, Maria
Athanasiou, Antonios
Arbyn, Marc
Lax, Sigurd F.
Raspollini, Maria Rosaria
Nieminen, Pekka
Carcopino, Xavier
Bornstein, Jacob
Guitekin, Murat
Paraskevaidis, Evangelos
LANCET ONCOLOGY, 2022, 23 (08): : E385 - E392
[7] Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024
Bryce, Alan H.
Agarwal, Neeraj
Beltran, Himisha
Hussain, Maha H.
Sartor, Oliver
Shore, Neal
Antonarakis, Emmanuel S.
Armstrong, Andrew J.
Calais, Jeremie
Carducci, Michael A.
Dorff, Tanya Barauskas
Efstathiou, Jason A.
Gleave, Martin
Gomella, Leonard G.
Higano, Celestia
Hope, Thomas A.
Iagaru, Andrei
Morgans, Alicia K.
Morris, David S.
Morris, Michael J.
Petrylak, Daniel P.
Reiter, Robert E.
Rettig, Matthew B.
Ryan, Charles J.
Sellinger, Scott B.
Spratt, Daniel E.
Srinivas, Sandy
Tagawa, Scott T.
Taplin, Mary-Ellen
Yu, Evan Y.
Zhang, Tian
Mckay, Rana R.
Koo, Phillip J.
Crawford, E. David
CANCER, 2025, 131 (01)
[8] Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease
Razak, Albiruni Ryan Abdul
Li, Louise
Bryant, Andrew
Diaz-Padilla, Ivan
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (03):
[9] 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
Besse, B.
Adjei, A.
Baas, P.
Meldgaard, P.
Nicolson, M.
Paz-Ares, L.
Reck, M.
Smit, E. F.
Syrigos, K.
Stahel, R.
Felip, E.
Peters, S.
ANNALS OF ONCOLOGY, 2014, 25 (08) : 1475 - 1484
[10] Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010
Felip, E.
Gridelli, C.
Baas, P.
Rosell, R.
Stahel, R.
VETERINARY RECORD, 2011, 169 (19) : 1507 - 1519

← 1 →